2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(benzofuran-5-ylmethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3H)-one | 1293915-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-((4-amino-3-(3-hydroxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)methyl)-3-(benzofuran-5-ylmethyl)-5-(6-morpholino-6-oxohex-1-yn-1-yl)quinazolin-4(3H)-one
• 英文别名: 2-[[4-Amino-3-(3-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-(1-benzofuran-5-ylmethyl)-5-(6-morpholin-4-yl-6-oxohex-1-ynyl)quinazolin-4-one
• CAS: 1293915-19-1
• 化学式: C₃₉H₃₄N₈O₅
• 分子量: 694.75
• InChiKey: FAPNBNUTFBHNBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  52
• 可旋转键数：
  9
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  165
• 氢给体数：
  2
• 氢受体数：
  10

文献信息

• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：RESPIVERT LTD

  公开号：WO2011048111A1

  公开（公告）日：2011-04-28

  The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their 10 compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.

  本发明涉及公式（I）的化合物，以及包含该化合物的组合物，以及化合物及其组合物在治疗中的使用，例如在治疗炎症性疾病，特别是呼吸道炎症性疾病的治疗中的使用。该发明还涉及制备上述化合物的方法。
• COMPOUNDS
  申请人：King-Underwood John

  公开号：US20120208799A1

  公开（公告）日：2012-08-16

  The present invention relates to compounds of formula (I) and to compositions comprising the same and to the use of the compounds and their compositions in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making said compounds.

  本发明涉及式(I)的化合物，以及包含这些化合物的组合物，以及这些化合物及其组合物在治疗中的用途，例如在治疗炎症性疾病，特别是呼吸道炎症性疾病的治疗中。该发明还涉及制备所述化合物的方法。
• QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
  申请人：Respivert Limited

  公开号：EP2491037B1

  公开（公告）日：2014-04-30
• A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES
  申请人：Psioxus Therapeutics Limited

  公开号：EP3007711B1

  公开（公告）日：2020-10-21
• A Dosing Regime and Formulations for Type B Adenovirus
  申请人：PSIOXUS THERAPEUTICS LIMITED

  公开号：US20160120922A1

  公开（公告）日：2016-05-05

  The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of 1×10 10 to 1×10 14 viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of 2×10 10 particles per minute to 2×10 12 particles per minute. The disclosure further extends to formulations of the said oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.